{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:50:53Z","timestamp":1794718253175,"version":"4.9.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>children &lt;5 years of age since the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in 2006 and its replacement with the 13-valent pneumococcal conjugate vaccine (PCV13) in 2010 in the United Kingdom.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Public Health England conducts enhanced national surveillance of invasive pneumococcal disease in England. Confirmed invasive pneumococcal disease cases diagnosed between September 1, 2006, and March 31, 2016, with hemolytic uremic syndrome reported as a complication were included in the analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There were 54 cases of pHUS during the surveillance period, with a median age of 17 months. The incidence of pHUS was 0.25\/100,000 during the PCV7 period and 0.08\/100,000 during the PCV13 period (incidence rate ratio: 0.31; 95% confidence interval: 0.16\u20130.57; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). Twelve children (22%) had an underlying comorbidity before disease onset. Overall, 31 (57%) presented with lower respiratory tract infection, 14 (25%) with meningitis, 8 (15%) with bacteremia and 1 (2%) with septic arthritis. An empyema was reported in 26\/31 children (84%) with lower respiratory tract infection and cerebral abscess in 5\/14 children (36%) with meningitis. The main responsible serotypes were 19A (n = 20), 3 (n = 6), 7F (n = 5) and 33F (n = 4). Eight children (15%) died, including 6 with meningitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>pHUS continues to be associated with significant morbidity and mortality. The incidence of pHUS was significantly lower after PCV13 replaced PCV7 in the childhood immunization program. Currently, most cases are due to non-PCV13 serotypes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002368","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T08:49:44Z","timestamp":1561020584000},"page":"e254-e259","source":"Crossref","is-referenced-by-count":21,"title":["Pneumococcal-related Hemolytic Uremic Syndrome in the United Kingdom"],"prefix":"10.1097","volume":"38","author":[{"given":"Ashley","family":"Makwana","sequence":"first","affiliation":[{"name":"Public Health England, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Sheppard","sequence":"additional","affiliation":[{"name":"Public Health England, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman K.","family":"Fry","sequence":"additional","affiliation":[{"name":"Public Health England, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez N.","family":"Ladhani","sequence":"additional","affiliation":[{"name":"Public Health England, London, United Kingdom"},{"name":"St. George\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240429","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome.","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"issue":"3, pt 2","key":"R2-20240429","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.lpm.2011.11.013","article-title":"Management of hemolytic uremic syndrome.","volume":"41","author":"Loirat","year":"2012","journal-title":"Presse Med"},{"key":"R3-20240429","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R4-20240429","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R5-20240429","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R6-20240429","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpeds.2007.03.055","article-title":"Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience.","volume":"151","author":"Waters","year":"2007","journal-title":"J Pediatr"},{"key":"R8-20240429","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3201\/eid1104.040833","article-title":"Childhood hemolytic uremic syndrome, United Kingdom and Ireland.","volume":"11","author":"Lynn","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"R9-20240429","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/INF.0b013e3181db03a7","article-title":"Epidemiology of Streptococcus pneumoniae-induced hemolytic uremic syndrome in Utah children.","volume":"29","author":"Bender","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20240429","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/INF.0b013e31828b31c8","article-title":"Trends in US hospital stays for Streptococcus pneumoniae-associated hemolytic uremic syndrome.","volume":"32","author":"Veesenmeyer","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20240429","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1542\/peds.2007-2017","article-title":"Streptococcus pneumoniae\u2013associated hemolytic uremic syndrome: classification and the emergence of serotype 19A.","volume":"125","author":"Copelovitch","year":"2010","journal-title":"Pediatrics"},{"key":"R12-20240429","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/INF.0b013e3182191c58","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America.","volume":"30","author":"Banerjee","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20240429","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/archdischild-2017-313923","article-title":"Pneumococcal haemolytic uraemic syndrome in the postvaccine era.","volume":"103","author":"Lawrence","year":"2018","journal-title":"Arch Dis Child"},{"key":"R14-20240429","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/adc.2008.148858","article-title":"Pneumococcal empyema and haemolytic uraemic syndrome in children: experience from a UK tertiary respiratory centre.","volume":"94","author":"Nyman","year":"2009","journal-title":"Arch Dis Child"},{"key":"R15-20240429","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumoniae associated hemolytic uremic syndrome.","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"R16-20240429","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/INF.0000000000001845","article-title":"Characteristics of children with invasive pneumococcal disease after the introduction of the 13-valent pneumococcal conjugate vaccine in England and Wales, 2010-2016.","volume":"37","author":"Makwana","year":"2018","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T18:08:06Z","timestamp":1714414086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002368"}},"subtitle":["National Surveillance, 2006\u20132016"],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002368","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}